Table 1 Characteristics of included COVID-19 intensive care unit survivors who received corticosteroid treatment versus without
No corticosteroids | Corticosteroids according to inclusion criteria | p-value | |
|---|---|---|---|
Total number, n | 68 | 181 | |
Follow-up time, months Md (IQR) | 5 (5–6) | 6 (5–8) | < 0.01 |
Age, years Md (IQR) | 57 (50–66) | 61 (53–68) | 0.06 |
Male n (%) | 54 (79) | 131 (72) | 0.33 |
BMI, kg/m2 Md (IQR) | 28 (25–31) | 29 (26–33) | 0.22 |
Diabetes n (%) | 12 (18) | 40 (22) | 0.49 |
Hypertension/cardio-vascular disease n (%) | 28 (41) | 97 (54) | 0.09 |
Chronic lung disease n (%) | 10 (15) | 40 (22) | 0.22 |
Ever smoker n (%) | 22 (32) | 83 (46) | 0.06 |
SAPS 3, Md (IQR) | 53 (49–57) | 57 (52–64) | < 0.01 |
Invasive ventilation n (%) | 32 (47) | 85 (47) | 1.0 |
Length of ICU stay (days), Md (IQR) | 8 (3–17) | 10 (7–20) | < 0.01 |